Kornimate/medical-research-clean huggingface dataset:
mental health outcome after surgery for obstructed defecation syndrome (ods)

Conditions: Surgery; Obstructive Defecation Syndrome; Mental Health Issue; Depression/Anxiety; Outcomes

Summary: background: obstructed defecation synsdrome (ods) causes people to strain and sometimes need help to go to the toilet. they think about going to the toilet a lot, which makes their lives worse. people with obstructed defecation synsdrome (ods) are more likely to be anxious and depressed than people with other illnesses. aim of the study: this study looked at how mental health affects obstructed defecation synsdrome (ods) patients before and after surgery.

aim, design, and setting of the study: this study measures the mental burden of obstructed defecation synsdrome (ods) in patients scheduled for surgery for obstructed defecation synsdrome (ods) before and 6 months after surgery. the results are linked to how well the bowel works. all scores are checked before surgery and at 6 months after. what do the investigators do to find this out ? the investigators look at patients' age, sex, body mass index (bmi), and other health problems. defecation symptoms are measured using a validated questionnaire, the altomare score, which has a maximum of 30 points. the rectal toxicity score reflects abdominal and bowel discomfort, which is determined by questions related to bowel dysfunction symptoms, such as diarrhea, meteorism, bleeding, and abdominal pain during bowel movement and defecation, and has a maximum of 32 points. the wexner score is a 20-point questionnaire for fecal incontinence symptoms. higher scores indicate greater severity of symptoms. mental disorders are evaluated using the personal health questionnaire 9 (phq-9) and general anxiety disorder 7 (gad-7). higher scores mean more severe symptoms. surgical procedure: for laparoscopic surgery under general anaesthesia, the patient is kept in a dorsal lithotomy position with their head down. the procedure opens the rectum, removes a part of the bowel and then rebuilds bowel continuity. the investigators collect data on how long the operation took, how long the patient stays in hospital, and how many people have complications after the operation. the scores will be reassessed at 6 months after surgery. for the clinical outcome, an improvement will be assumed at a reduction of 3 points and a strong improvement at a reduction of 6 points. similarly, deterioration and major deterioration will be assumed at an increase of 3 points and 6 points. the results will be analyzed statistically.

Eligibility criteria:
inclusion criteria: * obstructed defecation syndrome (ods) scheduled for surgery * conservative treatment failure * laparoscopic access possible exclusion criteria: • pregnancy

Keywords: mental health depression anxiety obstructed defecation syndrome surgery bowel resection rectopexy outcome follow up
uterine manipulator versus no uterine manipulator in endometrial cancer trial

Conditions: Endometrial Neoplasms

Summary: minimally invasive surgery is the recommended approach in endometrial cancer (ec) patients based on the results of two randomized controlled trials, given its advantages without compromised oncologic outcomes. the uterine manipulator is commonly used in benign and malignant pathologies to perform a laparoscopic or robotic hysterectomy. however, although regularly used, the uterine manipulator adoption in ec is a controversial technical aspect due to the raised concerns regarding the possible risk of disruption of the tumor mass, the spread of malignant cells, and seeding of the disease, particularly at the level of the vaginal cuff or spread of tumor cells, with increased risk of recurrence and death due to ec. on that basis, given that hysterectomy without a uterine manipulator is feasible, only a randomized controlled trial comparing oncologic outcomes in ec patients after use versus not use of the uterine manipulator will be able to provide high-quality evidence to answer this critical question and allow or exclude the use of a uterine manipulator during minimally invasive hysterectomy for ec.


Eligibility criteria:
inclusion criteria: * diagnosis of endometrial cancer of any histology (including carcinosarcoma) and grade * planned surgical treatment including hysterectomy and bilateral salpingo-oophorectomy (ovarian preservation in selected patients is not an exclusion criterion) * age ≥ 18 years * no preoperative evidence of extrauterine disease (clinical stage iiia, iiib) * no preoperative evidence of suspicious lymph nodes (clinical stage iiic) * no preoperative evidence of distant metastasis (clinical stage iv) * approved and signed informed consent exclusion criteria: * neoadjuvant therapy * synchronous or previous (\< 5 years) invasive cancer, not including non-melanoma skin cancer * fertility preservation * world health organization performance score \> 2 * uterine sarcoma * previous pelvic/abdominal radiotherapy, hormone therapy for cancer (\< 5 years), chemotherapy (\< 5 years), pelvic or paraaortic lymphadenectomy, or retroperitoneal surgery * inadequate bone marrow function (white blood cells \<3·0×109/l, platelets \<100×109/l) * inadequate liver function (bilirubin \>1.5×upper normal limit \[unl\], aspartate aminotransferase, and alanine aminotransferase \>2.5 × unl) * inadequate kidney function (creatinine clearance \< 60 ml per min calculated according to cockcroft-gault 10 or \< 50 ml per min ethylenediaminetetraacetic acid clearance) * intraoperative evidence of stage iv disease

Keywords: endometrial neoplasms uterine manipulator laparoscopic hysterectomy recurrence-free survival cause-specific survival overall survival oncologic outcomes
technical and clinical validation of the wpm-semg prototype

Conditions: Neuron Disease, Motor

Summary: validation study designed to demonstrate the technical and clinical performance, and the safety of a new medical device in healthy volunteers and patients with myopathy or neuropathy. the medical device is the wpm-semg prototype designed for recording electrophysiological signals of muscles.

the study consists of two parts: * the first part concerns the technical validation of the prototype. it will enrol 10 healthy volunteers (technical validation group). * the second part concerns the clinical validation of the prototype in comparison with the gold standard, that is the needle-emg. it will enrol 50 healthy volunteers (clinical validation group), including also the 10 subjects of the technical validation group, and 20 patients measurements will be done on 4 muscles with the wpm-semg device prototype using a rigid electrode matrix. for each muscle, the participant will execute some spontaneous motor activities and measurements will be taken on the muscle under tension (low, medium, and high) for a total of 12 measurements. measurements will be repeated two times after a pause for a total of 24 acquisitions. for the group with myopathies an additional fifth muscle, not foreseen by the protocol, can be done if considered the clinical most affected muscle followingthe neurological examination. a control intervention is done on the same subjects and consists in a needle-emg which will be applied as for routine clinical practice on the same muscles used for the wpm-semg device prototype. measurements will be taken for each muscles as for the rigid matrix.

Eligibility criteria:
eligibility criteria for healthy volunteers * inclusion criteria * healthy volunteers * female or male * 18 years or older * preserved cognitive capacity * ability to understand the study * willingness to complete all the study assessments * no chronic or concomitant use of medications or treatment * written informed consent * exclusion criteria * skin lesions in the area below the electrode * allergy to metal alloys * history of skin disease * pregnancy * lactation * known causes of neuromuscular disease * inability to follow the procedures of the study eligibility criteria for patients * inclusion criteria * patients of the neurocentro della svizzera italiana with diagnosis of myopathy or neuropathy that requires a needle-emg electrophysiological testing as standard clinical management of the disease * female or male * 18 years or older * preserved cognitive capacity * ability to understand the study * willingness to complete all the study assessments * no chronic or concomitant use of medications or treatment that may influence the measure in the opinion of the investigator (muscle relaxant such as baclofen, statin, benzodiazepine). * written informed consent * exclusion criteria * skin lesions in the area below the electrode * allergy to metal alloys * history of skin disease * cognitive and/or psychiatric disorders * pregnancy * lactation * neuromuscular disease other than myopathy and neuropathy * inability to follow the procedures of the study
effectiveness of training in reading rehabilitation for patients with diabetic macular oedema

Conditions: Diabetic Macular Oedema; Parafoveal Scotoma

Summary: diabetic macular oedema (dmo) is a sight-threatening problem for diabetic patient who has swelling in macula. patients with dmo can receive laser treatment and achieve good acuity finally. however, some patients still have difficulties in reading even after proper treatment. in this project, the investigators aimed to explore the effectiveness of different training paradigms in improving reading performance in patients with dmo.

patients with diabetic macular oedema (dmo), after receiving laser photocoagulation, achieved good outcomes in distance acuity. however, some patients, particularly those developing parafoveal scotoma, still had difficulty in reading. inability to read or reading very slowly leads to the potential loss of job, as well as the enjoyment of reading for leisure. in this study, the investigators aimed to investigate the effectiveness of reading rehabilitation using perceptual learning paradigms in enhancing reading performance in patients with reading difficulties due to dmo. also, the fundamental mechanisms explaining the reading problems in patients with dmo reading chinese will be examined. the investigators hypothesize that the perceptual training would show an improvement in reading. the investigators' primary hypothesis is that temporal visual processing speed and spatial visual span will be improved after perceptual training. the investigators' secondary hypothesis is that the reading speed and fixation stability will be improved after training.

Eligibility criteria:
inclusion criteria: * able to read chinese. * no formal vision rehabilitation training in reading after vision loss * diagnosis of diabetic macular oedema (dmo) and had previous treatment with laser and / or intravitreal injections * reasonable control of blood glucose level (hba1c \<10) to minimize the impact of vision fluctuation * education level of 6 years or more (primary school or above) exclusion criteria: * receive any types of eye treatments other than those mentioned above * any diagnosed ocular diseases other than dmo * severe medical problems or self reported neurological or cognitive disorders * serious hearing impairment * previously attended vision rehabilitation clinic

Keywords: diabetic macular oedema perceptual learning chinese hong kong
velocity vector imaging in patients with moderate-to-severe aortic regurgitation

Conditions: Aortic Regurgitation

Summary: velocity vector imaging may provide reliable and detailed information on left ventricular segmental function in asymptomatic patients with moderate-to severe ar. this may help to identify subclinical myocardial dysfunction in order to operate early enough to prevent postoperative heart failure and restrict unnecessary early operation which could be associated with operative risks and mortality related to prosthetic valves.

chronic aortic regurgitation (ar) is a progressive process which causes both left ventricular volume and pressure overload. while the volume overload is associated with the degree of the aortic regurgitant volume, the pressure overload occurs as a result of systemic hypertension developed due to increased stroke volume. in early stages, excentric hypertrophy occurs aiming to compensate the volume overload in the left ventricle. therefore , ejection fraction remains in normal range despite the increasing volume overload. left ventricular dilatation and impairment in ejection fraction only occur in the end stages of the disease. asymptomatic patients with chronic aortic regurgitation (ar) have a good prognosis in the presence of preserved systolic function. therefore it is a challenge to identify patients with subclinical left ventricular (lv) dysfunction. velocity vector imaging (vvi) is a new echocardiographic method based on two dimensional gray scale imaging, which is angle independent and can provide more accurate data about cardiac function.

Eligibility criteria:
inclusion criteria: * moderate-to-severe aortic regurgitation identified by standard echocardiography. * chronic isolated aortic regurgitation * being asymptomatic ( class 1 according to nyha) * sinusal rhythm exclusion criteria: * ejection fraction \< 50% * mitral valve disease accompanied to aortic regurgitation (patients with over mild degree of mitral regurgitation and stenosis * aortic stenosis * previous myocardial infarction, or the patients with \>50% coronary occlusion in any of the coronary arteries. * cardiomyopathies * av conduction disorders * chronic renal or hepatic insufficiency * malignities

Keywords: aortic regurgitation,velocity vector imaging
behavioral science aspects of rapid test acceptance

Conditions: HIV; Hepatitis C; Hepatitis B; Syphilis

Summary: the relevance of this research to public health is to make it possible to test for hepatitis c and syphilis at point of care so that people will receive their results immediately instead of requiring people to wait for at least a week to get their test results. this research will make rapid tests for hiv available that can detect hiv infection earlier and are more accurate than current tests available in the united states.

this application addresses "studies to improve access and utilization of hiv counseling and testing" for "hiv/aids and aids-related co-infections" such as "hepatitis c virus (hcv), other sexually transmitted infections (stis)" that are part of pa-07-307 drug abuse aspects of hiv/aids. the only rapid tests that are approved for use in the us currently are for hiv infection. tests for other conditions such as hepatitis c (hcv) and syphilis are in use in other countries. in response to an opportunity that the cdc published in the federal register, there are now candidate rapid test kits for hcv and syphilis available for experimental use in the us. different combinations of rapid and standard tests will be offered to participants in a four-arm trial to assess which tests are accepted by the participants. only a minority of clients at cbrs who have been offered the rapid test for hiv have accepted it. those who chose rapid hiv tests were more likely to be male, educated, gay, young and white. they were less likely to be black, or injection drug users. the proposed study has the potential to have a significant impact upon screening for hiv, syphilis, and hcv. rapid tests have the potential to increase the receipt of test results, particularly among groups that are less likely to return for their results using traditional testing. the candidate tests are designed for point of care (either oral fluid and/or whole blood), and thus will require real-time testing, so the trial will be able to evaluate both the accuracy of the tests in settings of intended use and their acceptability to potential clients in real-world situations.

Eligibility criteria:
inclusion criteria: * over 17 years old * mentally stable * sober * able to understand english or spanish * at least one good vein for phlebotomy * member of behavioral risk group

Keywords: diagnosis screening hiv serodiagnosis hcv antibodies serologic tests bedside testing diagnostic test kits syphilis serodiagnosis
study of azacytidine followed by gm-csf in patients with myelodysplastic syndrome (mds)

Conditions: Leukemia

Summary: the goal of this clinical research study is to learn if the combination of azacitidine and gm-csf can help to control mds. the safety of these drugs will also be studied. azacitidine is designed to block certain proteins that stop the function of tumor-fighting genes. by blocking the "bad" proteins, the tumor-fighting genes may be able to work better. granulocyte-macrophage colony-stimulating factor (gm-csf) is designed to help produce white blood cells. this may help to fight infections.

study drug administration: if you are found to be eligible to take part in this study, on days 1-4 of every cycle, you will receive azacitidine by vein over 15-30 minutes. you may receive drugs to help prevent nausea and vomiting before you receive your dose of azacitidine. on days 5-7 of every cycle, you will receive gm-csf by vein over about 15 minutes or by injection. each study cycle will be about 4-6 weeks, depending on the study doctor's decision. study visits: one (1) time each week during every cycle, blood (about 2-3 teaspoons) will be drawn for routine tests. at any time, if your doctor thinks it is needed, you will have a bone marrow aspirate to check the status of the disease. length of study: you may continue taking the study drugs for as long as the doctor thinks it is in your best interest. you will no longer be able to take the study drugs if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions. your follow-up visits will be per standard of care for the disease. this is an investigational study. both azacitidine and gm-csf are fda approved and commercially available for the treatment of mds. the study drug combination to treat mds is considered investigational. up to 40 patients will take part in this study. all will be enrolled at md anderson.

Eligibility criteria:
inclusion criteria: 1. patients with low- or intermediate-1-risk mds according to the international prognostic scoring system (ipss) classification 2. signed informed consent indicating that patients are aware of the investigational nature of this study in keeping with the policies of ut md anderson cancer center. 3. age \>/= 18 years old. 4. prior therapy with growth factor support, lenalidomide, or other investigational agents is allowed. 5. previously untreated patients are eligible for this study. exclusion criteria: 1. any previous adverse reaction (\>/= common terminology criteria for adverse events (ctcae) grade 2) to gm-csf. 2. prior treatment with azacytidine or decitabine. 3. unresolved diarrhea \>/= ctcae grade 2.

Keywords: leukemia myelodysplastic syndrome mds azacytidine 5-azacytidine 5-aza vidaza 5-azc aza-cr ladakamycin nsc-102816 gm-csf sargramostim leukine
acute effects of supplemental oxygen on memory testing in healthy adult volunteers

Conditions: Cognition

Summary: forty healthy adults (i.e., not recruited with respect to any particular diagnosis) are each alternately provided with supplemental oxygen and air via nasal cannula at about 6 liters per minute (lpm), while completing memory tests.

prior studies have reported that supplemental oxygen can confer acute benefits to cognition. here, the investigators seek to replicate/extend such findings by assessing whether such benefits can be seen using an inogen oxygen concentrator with subjects with an average age around 65 years old. the investigators include a standard measure of cognition previously reported to be sensitive to supplemental oxygen (2-back test) and a novel, in-development adaptation of a memory test for medical-related content (medical icons spatial test).

Eligibility criteria:
inclusion criteria: subjects are intended to represent "healthy adults." patients will include a mix of self-reported gender and ethnic/racial identification. 1. provision of signed and dated informed consent form 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. adult (aged 22+) exclusion criteria: * patients who self-report diagnosis of respiratory-related conditions will be excluded. * subjects with a known polyvinyl chloride (pvc) allergy will be excluded, due to potential use of a standard, pvc-based cannula in the study.

Keywords: oxygen concentrator hyperoxia
multimodal evaluation of cartilage lesions of patellofemoral joint

Conditions: Knee Osteoarthritis

Summary: evaluation and comparison of histological analysis, 9,4 tesla mri, full-field optical coherence tomography (ffoct) and ultrasound-based navigation system for cartilage degeneration analysis of patellofemoral joint.

knee osteoarthritis (oa) is a common and debilitating chronic degenerative disease of the articular cartilage. despite recent progress in the field of cartilage imaging, no routinely used clinical imaging modality has the ability to evaluate and monitor changes in cartilage degeneration. this observationnal, pilot, prospective, non randomized, uncontrolled, monocentric study aim to compare three of the most innovative imaging systems, namely the 9,4 tesla mri, the ffoct (full-field optical coherence tomography) and the ultrasound-based navigation system in order to image healthly to severely degraded human cartilage samples. all methods will be cross-correlated and compared with histological data considered as the gold standard.

Eligibility criteria:
inclusion criteria: * over 18 years of age * knee prosthetic surgery indication with cartilage excision. exclusion criteria: * subjects who refuse to sign a non-objection form

Keywords: knee joint cartilage degeneration ultrasound imaging full-field optical coherence tomography 9,4 tesla mri multimodal evaluation
study of the safety of ce 224,545 and methotrexate in patients with rheumatoid arthritis

Conditions: Arthritis, Rheumatoid

Summary: ce 224,535 is being developed for the treatment of rheumatoid arthritis. the purpose of this study is to evaluate the safety and tolerability of ce 224,535 after 4 weeks of treatment in subjects with rheumatoid arthritis already receiving methotrexate


Eligibility criteria:
inclusion criteria: * adults patients with rheumatoid arthritis * patients who have received stable weekly doses of oral methotrexate (5 to 25 mg/week administered as a single dose) for a minimum of 28 days (4 weeks/4 doses) exclusion criteria: * history of chronic infectious disease such as genitourinary, pulmonary or sinus infections. * any current or known malignancy or history of malignancy within the previous 5 years * pregnant or lactating women; women of child-bearing potential who are unwilling to unable to use an acceptable method of birth control during the study